FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321809039> ?p ?o ?g. }

• W2321809039 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCAntibody-drug conjugates (ADCs) represent a promising therapeutic modality for the clinical management of cancer. We sought to develop a novel ADC that targets 5T4 (TPBG), an oncofetal antigen expressed on tumor-initiating cells (TICs), which comprise the most aggressive cell population in the tumor. We optimized an anti-5T4 ADC (A1mcMMAF) by sulfydryl-based conjugation of the humanized A1 antibody to the tubulin inhibitor monomethylauristatin F (MMAF) via a maleimidocaproyl linker. A1mcMMAF exhibited potent in vivo anti-tumor activity in a variety of tumor models and induced long-term regressions for up to 100 days after the last dose. Strikingly, animals showed pathological complete response in each model. In a non-small cell lung cancer patient-derived xenograft in which 5T4 is preferentially expressed on the less differentiated tumor cells, A1mcMMAF treatment resulted in sustained tumor regressions and reduced TIC frequency. These results highlight the potential of ADCs that target the most aggressive cell populations within tumors. An optimized pharmacokinetic/pharmacodynamic (PK/PD) model of tumor growth and drug kill was used to characterize the ADC concentration response relationship in mouse. A holistic secondary parameter, tumor static concentration (TSC), was derived from model parameters to quantify efficacy and support early clinical trial design. Tumor static concentrations [80% confidence] of A1mcMMAF ranged from 1.1[0.9 -1.4] μg/ml to 11.6 [9.6 - 14.1] μg/ml across tumor models. For comparison, in the clinic T-DM1 has an average concentration of 14 μg/ml at an efficacious dose of 3.6 mg/kg Q3wk (HER+ breast cancer) (Krop et al. 2010) and Brentuximab-vedotin has an average concentration of 3.65 μg/ml at an efficacious dose of 1.8 mg/kg Q 3wk (HL/ ALCL) (Younes et al. 2010). Taken together, the preclinical data established a promising therapeutic index that supports clinical testing of A1mcMMAF. Expression analysis profiling using clinical and preclinical data indicated that lung and breast tumors demonstrated differentially high expression of 5T4 in comparison to normal tissues. An IHC assay developed in house confirmed the hypothesis that a broad range of 5T4 expression was measurable in NSCLC patient tumor samples. Additionally, we developed an assay that measures 5T4 expression on circulating tumor cells (CTCs) and used this assay to measure and characterize a broad range of 5T4 expression in CTCs obtained from the blood of NSCLC patients. We intend to deploy these co-developed immunoassays to guide A1mcMMAF clinical development.Citation Format: Puja Sapra, Marc Damelin, Kimberly Marquette, Kenneth G. Geles, Jonathon Golas, Maureen Dougher, Bitha Narayanan, Andreas Giannakou, Kiran Khandke, Russell Dushin, Elana Ernstoff, Judy Lucas, Mauricio Leal, George Hu, Alison Betts, Nahor Haddish-Berhane, Eric Powell, Steven Pirie-Shepherd, Christopher O'Donnell, Lioudmila Tchistiakova, Hans-Peter Gerber, Dena Marrinucci, Eric Tucker. Preclinical development and translational research on a novel antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4752. doi:10.1158/1538-7445.AM2013-4752" @default.
• W2321809039 created "2016-06-24" @default.
• W2321809039 creator A5002453971 @default.
• W2321809039 creator A5007306710 @default.
• W2321809039 creator A5008891572 @default.
• W2321809039 creator A5011372088 @default.
• W2321809039 creator A5011808781 @default.
• W2321809039 creator A5012091411 @default.
• W2321809039 creator A5014632539 @default.
• W2321809039 creator A5015529631 @default.
• W2321809039 creator A5019571545 @default.
• W2321809039 creator A5030938271 @default.
• W2321809039 creator A5033646993 @default.
• W2321809039 creator A5036129401 @default.
• W2321809039 creator A5038125908 @default.
• W2321809039 creator A5043332165 @default.
• W2321809039 creator A5049564431 @default.
• W2321809039 creator A5051181862 @default.
• W2321809039 creator A5052067361 @default.
• W2321809039 creator A5052939374 @default.
• W2321809039 creator A5054225054 @default.
• W2321809039 creator A5080525415 @default.
• W2321809039 creator A5086102379 @default.
• W2321809039 creator A5086295517 @default.
• W2321809039 creator A5090769437 @default.
• W2321809039 date "2013-04-15" @default.
• W2321809039 modified "2023-09-23" @default.
• W2321809039 title "Abstract 4752: Preclinical development and translational research on a novel antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells." @default.
• W2321809039 doi "https://doi.org/10.1158/1538-7445.am2013-4752" @default.
• W2321809039 hasPublicationYear "2013" @default.
• W2321809039 type Work @default.
• W2321809039 sameAs 2321809039 @default.
• W2321809039 citedByCount "0" @default.
• W2321809039 crossrefType "proceedings-article" @default.
• W2321809039 hasAuthorship W2321809039A5002453971 @default.
• W2321809039 hasAuthorship W2321809039A5007306710 @default.
• W2321809039 hasAuthorship W2321809039A5008891572 @default.
• W2321809039 hasAuthorship W2321809039A5011372088 @default.
• W2321809039 hasAuthorship W2321809039A5011808781 @default.
• W2321809039 hasAuthorship W2321809039A5012091411 @default.
• W2321809039 hasAuthorship W2321809039A5014632539 @default.
• W2321809039 hasAuthorship W2321809039A5015529631 @default.
• W2321809039 hasAuthorship W2321809039A5019571545 @default.
• W2321809039 hasAuthorship W2321809039A5030938271 @default.
• W2321809039 hasAuthorship W2321809039A5033646993 @default.
• W2321809039 hasAuthorship W2321809039A5036129401 @default.
• W2321809039 hasAuthorship W2321809039A5038125908 @default.
• W2321809039 hasAuthorship W2321809039A5043332165 @default.
• W2321809039 hasAuthorship W2321809039A5049564431 @default.
• W2321809039 hasAuthorship W2321809039A5051181862 @default.
• W2321809039 hasAuthorship W2321809039A5052067361 @default.
• W2321809039 hasAuthorship W2321809039A5052939374 @default.
• W2321809039 hasAuthorship W2321809039A5054225054 @default.
• W2321809039 hasAuthorship W2321809039A5080525415 @default.
• W2321809039 hasAuthorship W2321809039A5086102379 @default.
• W2321809039 hasAuthorship W2321809039A5086295517 @default.
• W2321809039 hasAuthorship W2321809039A5090769437 @default.
• W2321809039 hasConcept C111113717 @default.
• W2321809039 hasConcept C112705442 @default.
• W2321809039 hasConcept C121608353 @default.
• W2321809039 hasConcept C126322002 @default.
• W2321809039 hasConcept C147483822 @default.
• W2321809039 hasConcept C150903083 @default.
• W2321809039 hasConcept C159654299 @default.
• W2321809039 hasConcept C203014093 @default.
• W2321809039 hasConcept C207001950 @default.
• W2321809039 hasConcept C2776662205 @default.
• W2321809039 hasConcept C2776869981 @default.
• W2321809039 hasConcept C2777325958 @default.
• W2321809039 hasConcept C2777701055 @default.
• W2321809039 hasConcept C2908647359 @default.
• W2321809039 hasConcept C3019217517 @default.
• W2321809039 hasConcept C502942594 @default.
• W2321809039 hasConcept C542903549 @default.
• W2321809039 hasConcept C71924100 @default.
• W2321809039 hasConcept C86803240 @default.
• W2321809039 hasConcept C98274493 @default.
• W2321809039 hasConcept C99454951 @default.
• W2321809039 hasConceptScore W2321809039C111113717 @default.
• W2321809039 hasConceptScore W2321809039C112705442 @default.
• W2321809039 hasConceptScore W2321809039C121608353 @default.
• W2321809039 hasConceptScore W2321809039C126322002 @default.
• W2321809039 hasConceptScore W2321809039C147483822 @default.
• W2321809039 hasConceptScore W2321809039C150903083 @default.
• W2321809039 hasConceptScore W2321809039C159654299 @default.
• W2321809039 hasConceptScore W2321809039C203014093 @default.
• W2321809039 hasConceptScore W2321809039C207001950 @default.
• W2321809039 hasConceptScore W2321809039C2776662205 @default.
• W2321809039 hasConceptScore W2321809039C2776869981 @default.
• W2321809039 hasConceptScore W2321809039C2777325958 @default.
• W2321809039 hasConceptScore W2321809039C2777701055 @default.
• W2321809039 hasConceptScore W2321809039C2908647359 @default.
• W2321809039 hasConceptScore W2321809039C3019217517 @default.
• W2321809039 hasConceptScore W2321809039C502942594 @default.
• W2321809039 hasConceptScore W2321809039C542903549 @default.
• W2321809039 hasConceptScore W2321809039C71924100 @default.
• W2321809039 hasConceptScore W2321809039C86803240 @default.
• W2321809039 hasConceptScore W2321809039C98274493 @default.
• W2321809039 hasConceptScore W2321809039C99454951 @default.
• W2321809039 hasLocation W23218090391 @default.

• next